Kyverna Therapeutics

IPO

Kyverna is Developing Cell Therapies for Autoimmune Diseases

Public · Emeryville, United States · Founded 2018 · $110.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$110.0M
Last Round
$85.0M Extension RoundAug 2023
Rounds
3
Type
Public

About

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies designed to achieve treatment-free remission in autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (KYV-101), is in Phase 2 trials across lupus nephritis, multiple sclerosis, myasthenia gravis, and stiff-person syndrome. Kyverna went public on Nasdaq in February 2024.

Summary

Kyverna Therapeutics is a Healthcare company based in Emeryville, United States, founded in 2018. It has raised $110.0M in total across 3 rounds, most recently a $85.0M Extension Round round in Aug 2023. Investors include Gilead Sciences and Vida Ventures.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Debt FinancingDebt FinancingNov 2025
$150.0M

Sign up to see all 5 rounds

Extension Round through Debt Financing — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Kyverna Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/kyverna-therapeutics"><img src="https://indexed.vc/api/badge/company/kyverna-therapeutics" alt="Kyverna Therapeutics on Indexed.vc" width="260" height="76" /></a>